DE602004022632D1 - Verwendung von adiponectin zur diagnose von krebs - Google Patents

Verwendung von adiponectin zur diagnose von krebs

Info

Publication number
DE602004022632D1
DE602004022632D1 DE602004022632T DE602004022632T DE602004022632D1 DE 602004022632 D1 DE602004022632 D1 DE 602004022632D1 DE 602004022632 T DE602004022632 T DE 602004022632T DE 602004022632 T DE602004022632 T DE 602004022632T DE 602004022632 D1 DE602004022632 D1 DE 602004022632D1
Authority
DE
Germany
Prior art keywords
cancer
adiponectin
diagnosis
disclosed
epithelial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004022632T
Other languages
English (en)
Inventor
Christos S Mantzoros
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beth Israel Deaconess Medical Center Inc
Original Assignee
Beth Israel Deaconess Medical Center Inc
Beth Israel Hospital Association
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Deaconess Medical Center Inc, Beth Israel Hospital Association filed Critical Beth Israel Deaconess Medical Center Inc
Publication of DE602004022632D1 publication Critical patent/DE602004022632D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57442—Specifically defined cancers of the uterus and endometrial
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE602004022632T 2003-01-09 2004-01-09 Verwendung von adiponectin zur diagnose von krebs Expired - Lifetime DE602004022632D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43908803P 2003-01-09 2003-01-09
PCT/US2004/000410 WO2004063711A2 (en) 2003-01-09 2004-01-09 Use of adiponectin to diagnose and treat malignancy

Publications (1)

Publication Number Publication Date
DE602004022632D1 true DE602004022632D1 (de) 2009-10-01

Family

ID=32713428

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004022632T Expired - Lifetime DE602004022632D1 (de) 2003-01-09 2004-01-09 Verwendung von adiponectin zur diagnose von krebs

Country Status (4)

Country Link
EP (1) EP1585987B1 (de)
AT (1) ATE440284T1 (de)
DE (1) DE602004022632D1 (de)
WO (1) WO2004063711A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005031345A2 (en) * 2003-09-27 2005-04-07 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor adipor2 (adipor2)
EP1685846B1 (de) * 2003-11-04 2014-11-26 Daiichi Sankyo Company, Limited Antitumorales mittel
US7678886B2 (en) 2005-01-07 2010-03-16 Xencor, Inc. Pharmaceutical compositions of adiponectin variants and methods of storage
US7749956B2 (en) 2005-01-07 2010-07-06 Xencor, Inc. Method of treatment using adiponectin variants
US7592423B2 (en) 2005-01-07 2009-09-22 Xencor, Inc. Globular adiponectin variants
US8093017B2 (en) 2005-12-07 2012-01-10 Siemens Heathcare Diagnostics Inc. Detection of soluble adiponectin receptor peptides and use in diagnostics and therapeutics
EP2215268B1 (de) 2007-11-30 2018-08-29 Siemens Healthcare Diagnostics Inc. Adiponectin-rezeptorfragmente und verwendungsverfahren
WO2010123720A1 (en) * 2009-04-23 2010-10-28 Siemens Healthcare Diagnostics Inc. Monomeric and dimeric forms of adiponectin receptor fragments and methods of use
KR102402428B1 (ko) * 2021-06-18 2022-05-31 주식회사 레지온 난소암 진단용 다중 바이오 마커 및 이의 용도

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002513295A (ja) * 1997-07-08 2002-05-08 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド １２３種類のヒト分泌タンパク質
FR2767135B1 (fr) * 1997-08-06 2002-07-12 Genset Sa Recepteur complexe lsr, activite, clonage, et application au diagnostic, a la prevention et/ou au traitement de d'obesite et des risques ou complications associes
JPWO2002061076A1 (ja) * 2001-02-01 2004-06-03 持田製薬株式会社 アディポネクチン関連蛋白質

Also Published As

Publication number Publication date
EP1585987B1 (de) 2009-08-19
WO2004063711A3 (en) 2004-09-16
ATE440284T1 (de) 2009-09-15
EP1585987A2 (de) 2005-10-19
WO2004063711A2 (en) 2004-07-29

Similar Documents

Publication Publication Date Title
Di Palma et al. Salivary duct carcinomas can be classified into luminal androgen receptor‐positive, HER2 and basal‐like phenotypes
DE60214134D1 (de) Modifizierte psma-liganden und deren verwendung
DK2199801T3 (da) Biomarkører til tidlig påvisning af ovariecancer
ATE430936T1 (de) Verwendung von cyfra 21-1 und osteopontin als marker für kolorektalkarzinome
WO2006089212A3 (en) Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin
HK1083366A1 (en) Diagnosing tumorigenicity and determining resistance to anticancer therapy
ATE365922T1 (de) Verfahren zur erkennung von eierstockkrebs mittels menschlichem kallikrein (hk6)
SG165370A1 (en) Method for the diagnosis of colorectal cancer and ovarian cancer by the measurement of vitamin e-related metabolites
ATE513216T1 (de) Verwendung des proteins satb2 als prognostischer marker für kolorektalkarzinome
ATE459883T1 (de) Neue proliferationsmarker in der klinischen praxis und deren verwendung zur krebsprognose oder -diagnose
WO2006078911A3 (en) Gitr antibodies for the diagnosis of nsclc
Hwang et al. Prognostic influence of BCL2 on molecular subtypes of breast cancer
CA2701341A1 (en) Method of assessing colorectal cancer from a stool sample by use of the marker combination calprotectin and hemoglobin/haptoglobin complex
DE602004022632D1 (de) Verwendung von adiponectin zur diagnose von krebs
Tsang et al. Nerve growth factor receptor (NGFR): a potential marker for specific molecular subtypes of breast cancer
Kachrilas et al. PI3K/AKT pathway genetic alterations and dysregulation of expression in bladder cancer
Gadducci et al. Is perineural invasion a novel prognostic factor useful to tailor adjuvant treatment in patients treated with primary surgery for cervical and vulvar carcinoma?
DK1631686T3 (da) Påvisning af dysplasi i høj grad i cervicale celler
ATE350662T1 (de) Markerproteine für prostatakrebs
ATE545867T1 (de) I-plastin-testverfahren zur in-vitro-diagnose von kolorektalkarzinom
ATE426168T1 (de) Verwendung von asc als marker fur kolorektalkarzinome
WO2003073821A3 (en) Shc PROTEIN-RELATED METHODS AND COMPOSITIONS FOR THE PROGNOSIS OF BREAST, PROSTATE AND OVARIAN CANCER
ATE491727T1 (de) Zusammensetzungen und deren verwendungen zur identifizierung und zum targetting von provasopressinexprimierenden krebszellen
Mhawech-Fauceglia et al. Role of the tumour necrosis family ligand APRIL in solid tumour development: Retrospective studies in bladder, ovarian and head and neck carcinomas
DE602004017317D1 (de) Verwendung der proteine proteinase 3 (prn3) und leukozyten elastatse inhibitor (ileu) als marker für kolorektale karzinome

Legal Events

Date Code Title Description
8364 No opposition during term of opposition